Subscribe To
23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610 Phase 1/2a clinical trial in patients with advanced solid malignancies SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced two poster presentations on 23ME-00610, […] The post 23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, a...
Read More
Posted: Sep 27 2023, 20:05
Author Name: forextv
Views: 112281